Gold prices hit 4-month high on Fed easing hopes, tariff uncertainty
Scott B. Ullem, Chief Financial Officer of Edwards Lifesciences Corp (NYSE:EW), recently sold a significant portion of his holdings in the company. According to a recent SEC filing, Ullem sold 11,250 shares of the company’s common stock on March 26, 2025, at an average price of $70.8682 per share, totaling approximately $797,267. The transaction occurred near the current trading price of $71.09, with InvestingPro data showing the stock trading at Fair Value levels. This transaction was part of a Rule 10b5-1 trading plan that Ullem had adopted in August 2024.
In addition to the stock sale, Ullem also exercised stock options to acquire 11,250 shares at a price of $45.2767 each, with the total value of these options amounting to $509,362. Following these transactions, Ullem’s direct ownership stands at 30,387 shares, with additional shares held indirectly through a trust. The transactions reflect changes in Ullem’s beneficial ownership of Edwards Lifesciences, a company known for its innovations in heart valve systems and critical care monitoring. With 11 analysts recently revising earnings estimates upward and a robust gross profit margin of 79.5%, detailed insights on EW’s valuation and growth prospects are available through the comprehensive Pro Research Report on InvestingPro.
In other recent news, Edwards Lifesciences reported fourth-quarter 2024 financial results that exceeded analyst expectations. The company achieved a revenue of $1.39 billion, surpassing the anticipated $1.36 billion, and an adjusted earnings per share (EPS) of $0.59, beating the forecast of $0.55. The Transcatheter Aortic Valve Replacement (TAVR) segment generated $1.04 billion in revenue, marking a 5.3% year-over-year increase, while the Transcatheter Mitral and Tricuspid Therapies (TMTT) division saw an impressive 85% growth, reaching $105.1 million. Canaccord Genuity raised its price target for Edwards Lifesciences to $71, maintaining a Hold rating, while Stifel reaffirmed a Buy rating with a $90 target, reflecting confidence in the company’s growth trajectory. The strong performance was attributed to favorable foreign exchange effects and robust sales in the TAVR and TMTT segments. Edwards Lifesciences reiterated its 2025 financial guidance, projecting total company sales between $5.6 billion and $6.0 billion, with an expected growth rate of 8-10%. The company also highlighted strategic acquisitions and a focus on structural heart disease as key drivers for future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.